Opdualag Approved for Unresectable, Metastatic Melanoma
Opdualag is a fixed-dose combination of nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody.
Melanoma And Other Skin Cancers
Keytruda Approved for Adjuvant Treatment IIB, IIC Melanoma Following Resection
Approval was based on data from the phase 3 KEYNOTE-716 trial, which enrolled 976 participants.
Relatlimab-Nivolumab Fixed-Dose Combo Gets Priority Review for Melanoma
The application is supported by data from the phase 2/3 RELATIVITY-047 trial.
Nemvaleukin Alfa Fast Tracked for Mucosal Melanoma
Nemvaleukin alfa is an investigational, engineered fusion protein consisting of modified interleukin-2 (IL-2) and the high-affinity IL-2 alpha receptor chain.
Lymphoseek Approval Expanded to Pediatric Patients
The approval was based on data from a phase 2 trial that assessed Lymphoseek in pediatric patients with melanoma, RMS, or other solid tumors.
- Loading...
Loading...
Next post in News
Loading... 
Loading...